Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
Core evidence2009Vol. 4, pp. 43–43
Citations Over TimeTop 17% of 2009 papers
Abstract
To date, in phase II clinical studies axitinib has demonstrated antitumor activity in advanced refractory thyroid cancer. As a monotherapy it resulted in a 30% response rate with another 38% of patients having stable disease. Axitinib appears to have a good tolerability profile, with hypertension being the most common grade 3 or greater side effect.
Related Papers
- → Axitinib in the Treatment of Metastatic Renal Cell Carcinoma(2011)37 cited
- → Targeted treatments in advanced renal cell carcinoma: focus on axitinib(2014)10 cited
- → Axitinib for the Treatment of Metastatic Renal Cell Carcinoma(2016)8 cited
- → Axitinib in renal cell carcinoma: now what do we do?(2014)
- Progress in the research of axitinib in the treatment of renal cell carcinoma(2014)